Sort   by:  
 Page size 
UnknownIncreased CK5/CK8-positive intermediate cells with stromal smooth muscle cell atrophy in the mice lacking prostate epithelial androgen receptor.
Not available
S-EPMC3130731 | biostudies-literature
UnknownAntiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.
Not available
S-EPMC4704455 | biostudies-literature
UnknownTR4 nuclear receptor suppresses HCC cell invasion via downregulating the EphA2 expression.
Not available
S-EPMC5833398 | biostudies-literature
UnknownInfiltrating mast cells increase prostate cancer chemotherapy and radiotherapy resistances via modulation of p38/p53/p21 and ATM signals.
Not available
S-EPMC4811464 | biostudies-literature
UnknownCisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
Not available
S-EPMC4887098 | biostudies-literature
UnknownC1QBP Regulates YBX1 to Suppress the Androgen Receptor (AR)-Enhanced RCC Cell Invasion.
Not available
S-EPMC5247285 | biostudies-literature
UnknownAndrogen receptor increases hematogenous metastasis yet decreases lymphatic metastasis of renal cell carcinoma.
Not available
S-EPMC5640635 | biostudies-literature
UnknownPreclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9® to Suppress Enzalutamide-resistant Prostate Cancer Progression.
Not available
S-EPMC5802348 | biostudies-literature
UnknownTR4 nuclear receptor enhances the cisplatin chemo-sensitivity via altering the ATF3 expression to better suppress HCC cell growth.
Not available
S-EPMC5077999 | biostudies-literature
UnknownPreclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling.
Not available
S-EPMC5938119 | biostudies-literature
Sort   by:  
 Page size